Agendia announces companion diagnostics agreement with Daiichi Sankyo - Gilde Healthcare

Agendia announces companion diagnostics agreement with Daiichi Sankyo

April 25, 2014

IRVINE, CA and AMSTERDAM – Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.

“This exciting early stage research collaboration represents a potential new area for additional commercialization and expansion of Agendia’s platform technology,” said David Macdonald, Agendia’s President and CEO. “We are very pleased to apply our expertise to assist with the potentially groundbreaking work being done by Daiichi Sankyo.”

Macdonald noted that Agendia has a long history of providing clinically valuable information about gene expression in oncology. “With this new agreement, our molecular diagnostics technology will now be applied to additional areas of oncology research,” he said.

As part of the agreement between Agendia and Daiichi Sankyo, Agendia technology will be used to assess patient samples. Terms and other aspects of the agreement were not disclosed.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. For more information, visit www.daiichisankyo.com.

About Agendia (www.agendia.com)

Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer suite was developed using an unbiased gene selection by analyzing the complete human genome. This includes MammaPrint, as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology, and TargetPrint®, an ER/PR/HER2 expression assay. MammaPrint is the only breast cancer recurrence assay back by peer-reviewed, prospective outcome data. These tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com.

Gilde Healthcare company NIZO participates in national consortium investing in precision fermentation scale-up facility

The Netherlands is strengthening its position as a global leader in cellular agriculture with the launch of two independent, open-access scale-up facilities. These facilities, developed in a collaboration between NIZO Food Research, Cultivate at Scale...
February 4, 2025

Gilde Healthcare company GT Medical Technologies raises $37 million in to advance GammaTile® for patients with operable brain tumors

GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced the company has completed a $37 million first close of...
January 17, 2025

Alleviant Medical Secures $90 Million Financing to Expand Interventional Heart Failure Pivotal Trial Program

Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, today announced a $90 million financing to fund its second pivotal trial. Led by Gilde Healthcare, the round also...
January 14, 2025